Woebot Health

Woebot Health

Enterprise AI chatbot for mental health with FDA Breakthrough designation for postpartum depression.

About Woebot Health

Woebot Health is a clinical-grade AI mental health platform that uses a rule-based conversational chatbot (not generative AI) to deliver evidence-based therapeutic techniques including CBT, DBT, and IPT. The company received FDA Breakthrough Device Designation in 2021 for WB001, its investigational digital therapeutic for postpartum depression, and has been conducting pivotal clinical trials. In June 2025, Woebot discontinued its direct-to-consumer app to focus entirely on enterprise partnerships with payers, providers, and health systems. The platform is backed by 15+ randomized controlled trials showing effect sizes of d=0.57 for anxiety and d=0.46 for depression. Enterprise revenue comes from Per Member Per Month (PMPM) subscriptions and per-treatment cycle fees ($200-$450). Notable partnerships include Akron Children's Hospital for adolescent mental health. The 2025 Open Access API enables third-party healthcare apps to embed Woebot's conversational interface.

Best For

  • Health systems seeking AI-augmented mental health support
  • Payers implementing scalable behavioral health interventions
  • Pediatric hospitals providing adolescent mental health support
  • Employers wanting evidence-based digital mental health

Not Ideal For

  • Individual consumers (DTC app discontinued June 2025)
  • Solo practitioners
  • Organizations seeking traditional MBC assessment tools
  • Those wanting FDA-cleared products (still in trials for PPD)

Pricing

Contact for enterprise pricing

Compliance & Security

HIPAAYes
BAA AvailableYes
SOC 2Unknown
HITRUSTUnknown

Always verify compliance directly with the vendor.

Target Audience

Roles

PsychiatristPsychologist

Settings

Multi-Site / Enterprise

Get Started

Try Woebot Health for your practice.

Visit Woebot Health